London Stock Exchange welcomes Trellus Health plc to AIM

London Stock Exchange today welcomes Trellus Health plc (“Trellus” or the “Company”), a leading resilience-driven connected health solution for chronic conditions, to celebrate the listing of the Company's public shares onto AIM, under the ticker "TRLS". The Company is incorporated in England and Wales with US headquarters in White Plains, NY.

Trellus Health is commercialising the provision of digital chronic condition management solutions for health plans and employers that utilise the scientifically validated Gaining Resilience Through Transitions (GRITT™) methodology and a proprietary HIPAA compliant technology platform called TrellusElevate™, to coordinate and deliver personalised care remotely via telemedicine. 

The GRITT™ methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85% reduction in emergency department visits and hospitalisations. The Company is initially focused on Inflammatory Bowel Diseases (“IBD”), which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but also considers its approach to have potential utility and demand across many chronic conditions.

Trellus received a USD5 million Seed investment from London-listed EKF Diagnostics Holdings PLC in August 2020, in partnership with the Icahn School of Medicine at Mount Sinai (“ISMMS”). In conjunction with the Seed financing, Trellus secured the exclusive worldwide license from ISMMS to commercialise the patent-pending GRITT™ methodology for IBD and seven chronic conditions including diabetes, kidney disease, cardiovascular disease, auto-immune conditions, and cancer. Additionally, the company has successfully raised £28.5 million in total on 20 May 2021, which includes the gross proceeds of £27.6 million from the placing and subscription, plus £0.9 million from the Restricted Offer. The company’s market capitalisation is approximately £64.6 million on admission, and all 2,250,000 Ordinary Shares available under the Restricted Offer were issued.

Monique Fayad, Chief Executive Officer of Trellus Health, said: “I would like to thank our dedicated colleagues, advisors, investors and shareholders, who made this transaction happen. We are incredibly proud to have reached this important milestone, as our AIM IPO will enable us to scale our business and technology platform in the US and abroad. 

I look forward to Trellus Health continuing to provide valuable solutions by using the GRITT™ methodology and our resilience-driven multidisciplinary care model, to leverage expert whole-person care, data science and technology to deliver personalised and more cost-effective care for all people living with chronic conditions.”

Dr. Marla Dubinsky, Co-Founder and Non-Executive Board Director of Trellus Health, said: “After experiencing the significant positive outcomes of the GRITT™ methodology at our leading academic medical centre, we are delighted that Trellus Health’s AIM financing will enable the company to scale this validated approach and multidisciplinary care model to all people living with IBD, regardless of their geographic location.  

The COVID-19 pandemic heightened global awareness of the importance of resilience and connectivity to address the physical and emotional needs of all people, not only those living with chronic conditions. Over the last year, clinicians and patients have grown accustomed to the convenience and efficiency of digital health and telemedicine interactions, which will have a lasting impact on the delivery and coordination of whole-person care for patients living with complex chronic conditions. Trellus Health’s AIM financing will further allow us to meet patients where they are, while remotely monitoring them for rising risk indicators to predict and prevent costly unplanned and inappropriate care.”

To find out more about Trellus Health PLC, please visit: 

Strictly Come Dancing/Dancing with the Stars celebrity, Amy Dowden, recently revealed her lifelong battle with Crohn’s disease and has agreed to become an ambassador for Trellus Health (official announcement to be made in due course). In the meantime, you can see her video testimonial here:

Quick facts

Market: AIM
Instrument market cap (£m)
Listing/Admission to trading
28 May 2021
Looking for new and recent issues?

More recent

London International Shipping Week 2021

London International Shipping Week 2021 (LISW21) is seen throughout the world as the ‘must attend’ international maritime event of the year. London is the historic centre of global trade and world shipping and stands at the heart of international commerce. Its long-standing maritime institutions have been servicing the global shipping industry for centuries and that role co

Learn more
London Stock Exchange welcomes LungLife AI

London Stock Exchange welcomes LungLife AI, Inc. to trading on AIM. In July 2021 LungLife successfully raised gross proceeds of £17 million and the Company’s market capitalisation on admission was £45 million with a free float of 50.6%. 

LungLife AI’s mission is to make a significant impact in the early detection of lung cancer. The Company is a develop

Learn more
London Stock Exchange welcomes Likewise Group plc to AIM

Likewise is a UK distributor of both domestic and commercial floorcoverings and matting. It is challenging the established competitors in the industry by providing access to a wide choice of flooring from multiple manufacturers across the globe at competitive prices for its customers. The Directors believe they have an opportunity to build a

Learn more
London Stock Exchange welcomes BiVictriX Therapeutics plc

London Stock Exchange today welcomes BiVictriX Therapeutics plc (“BiVictriX”), a rapidly emerging drug discovery and development company that begins trading on AIM under the ticker symbol BVX, following a successful initial public offering.

BiVictriX has successfully raised gross proceeds of £

Learn more